Ultragenyx Pharmaceutical Inc.
RARE
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
65.2% upsideUndervalued by 65.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.03 Billion |
|---|---|
| Enterprise Value | $4.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.83 |
| Beta | 0.38 |
| Outstanding Shares | 100,600,000 |
Return
| Return on Equity | 258.21% |
|---|---|
| Return on Assets | -47.02% |
| Return on Invested Capital | -56.47% |
Valuation & Multiples
| P/E Ratio | -5.04 |
|---|---|
| PEG | -22.43 |
| Price to Sales | 5.58 |
| Price to Book Ratio | -11.16 |
| Enterprise Value to Revenue | 6.06 |
| Enterprise Value to EBIT | -7.4 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | -5.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7164▲ 7.56% |
|---|---|
| Total Calls | 1,254,900▼ 57.82% |
| Total Puts | 899,000▼ 52.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.50%▲ 4.22% |
|---|---|
| Total Invested | $2.05B▼ 5.01% |
| Investors Holding | 311▼ 10.00% |
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis Relevant Senate Committees
Controls taxation, trade, and entitlement spending (e.g., Medicare pricing), which directly impacts corporate valuations, drug reimbursement, and overall market access for pharmaceutical companies.
Allocates federal spending, with subcommittees determining funding for health agencies (FDA, NIH) and government healthcare programs, directly impacting the operational environment and potential revenue streams for pharmaceutical companies.
Directly regulates the FDA (drug approval process), NIH (research funding), and impacts labor laws, making it a primary committee with direct oversight and influence on pharmaceutical companies.
Oversees antitrust laws and intellectual property; patent protection is fundamental to pharmaceutical companies, making this committee's influence on IP law and enforcement highly relevant.